Reported by: Emon Crwenewswire Correspondent

Las Vegas, NV December 31, 2010 (CRWENEWSWIRE) - Pfizer Inc announced formally that the pharmaceutical giant is planning to acquire Synbiotics Corporation. According to Pfizer’s Division of Animal Health President Mr. Juan R Alaix, this step will help the company to realize its goal of providing state of the art animal health products and facilities as the acquisition would equip Pfizer with enhanced research and development base and the best production facility for these products.

Pfizer’s move is a wise decision in a time when the industry is rapidly growing with an 8% growth rate annually while the immunodiagnostics market has a current worth of $735 million. The cautiousness of various pet owners for their animals according to their health and fitness is a key factor among many, which is helping to boost the industry beyond standards and Pfizer’s move in such a growing time could make profitable deals in the future.

Synbiotics mainly conducts its business with the provision of health services to animals and also provides immunodiagnostic facility for the detection of diseases in the animals. According to some officials at Pfizer, this acquisition will help the company in various aspects including the capacity enhancements for providing products for diagnostic and reproductive activities and will also help the company in increasing its health market with the provision of veterinary products and services.

Pfizer Inc is mainly a healthcare company that is involved in the production of medicine and diagnostic materials for various diseases. The Company conducts its global research programs for the improvement of health facilities and every-day life with the provision of state of the art medical services and products. Pfizer not only manufactures medicine and health therapies for humans, but is also actively involved in the production of diagnostics and therapies for animal health and wellness.

*******************************************

The Views and Opinions Expressed by the author are his or her opinions only and do not necessarily reflect those of this Web-Site or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company or person mentioned or referred to in the article.